News|Articles|March 6, 2026

7 Allergy Headlines You Missed in February 2026

Fact checked by: Tim Smith

This month in review features 7 allergy headlines in February 2026: FDA's decision on Dupilumab for AFRS, late-breaking data presented at AAAAI, & more.

February 2026 brought several notable developments across allergy and immunology, spanning regulatory decisions, updated clinical guidance, and emerging research presented at the 2026 American Academy of Allergy, Asthma, & Immunology annual meeting in Philadelphia from February 27 to March 2. From the US Food and Drug Administration (FDA) approval of dupilumab for allergic fungal rhinosinusitis to a Complete Response Letter for dibutepinephrine (Anaphylm), the month reflected both progress and ongoing hurdles in therapeutic development.

Related to this article

October 15th, 2026

Alpha-Gal Syndrome Moves North, Yet Diagnoses Lag Behind

Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.

Haley B. Naik, MD | Image credit: HS Foundation

October 21st, 2026

AAD's New HS Guidelines Flag 'Step Therapy' as Top Barrier to Care

AAD and HSF issued the first joint hidradenitis suppurativa guidelines, outlining 37 recommendations and flagging step therapy as a major barrier.

Xia Wang, MMed | Image Credit: The George Institute

October 21st, 2026

TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk

A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.

Dimitri Hemelsoet, MD | Image Credit: ResearchGate

October 21st, 2026

BIOX-101 Displays Safety and Efficacy in Spontaneous Intracerebral Hemorrhage

Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.

October 21st, 2026

Stroke Etiology Modifies Tenecteplase’s Effect Before Endovascular Thrombectomy

A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.